Loading...
welcome lifesaving.clinic

Bortezomib

TOP GENERIC CHOICE
Brand Name :
N/A
Generic Name :
Bortezomib
Price per Pill :
$179.16
Availablity :
In stock
Manufacture :
Various
This product is offered for sale by
GHE Healthcare Pvt Ltd
6 Vials
$225.83
$1355.00
12 Vials
$191.60
$2299.20
24 Vials
$179.16
$4299.84
Quantity:
addtocart
*Prescription Required

BORTEZOMIB Product Description

BORTEZOMIB is a chemotherapy drug in the pharmacologic class of proteasome inhibitors available for intravenous injection or subcutaneous use only. Each single dose vial of BORTEZOMIB contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder. Inactive ingredient: 35 mg mannitol, USP. BORTEZOMIB is indicated for treatment of patients with multiple myeloma who have received and treatment of patients with mantle cell lymphoma. It is used in combination with drugs like cyclophosphamide,rituximab, doxorubicin and oral prednisone. BORTEZOMIB is not an over the counter drug and one has to have a valid doctor’s prescription before acquiring the drug.

BORTEZOMIB PRESCRIBING INFORMATION

The recommended starting dose of BORTEZOMIB is 1.3 mg/m2. BORTEZOMIB may be administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/ml. BORTEZOMIB injection is administered as a 3 to 5 second bolus. BORTEZOMIB is for intravenous or subcutaneous use only. It should not be administered by any other route.

BORTEZOMIB dosing in previously untreated Multiple Myeloma (ADULT)

  • BORTEZOMIB is administered in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles. BORTEZOMIB dose is 1.3 mg/m2, Melphalan at 9 mg/m2 and Prednisone at 60 mg/m2
  • At least 72 hours should elapse between consecutive doses of BORTEZOMIB.

BORTEZOMIB dosing in previously untreated Mantle cell lymphoma (ADULT)

  • BORTEZOMIB (1.3 mg/m2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for six 3-week treatment cycles. BORTEZOMIB is administered first followed by rituximab. BORTEZOMIB is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period on Days 12-21. For patients with a response first documented at cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of BORTEZOMIB.
  • Rituximab dose at 375 mg/m2, Cyclophosphamide dose at 750 mg/m2, doxorubicin dose at 50 mg/m2, Oral prednisone at 50 mg/m2.

BORTEZOMIB dosing for Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma (ADULT)

  • BORTEZOMIB (1.3 mg/m2/dose) is administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, BORTEZOMIB may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35). At least 72 hours should elapse between consecutive
  • BORTEZOMIB therapy should be withheld at the onset of any Grade 3 non-hematological or Grade 4 hematological toxicities excluding neuropathy
Patients with moderate or severe hepatic impairment should be started on BORTEZOMIB at a reduced dose of 0.7 mg/m2 per injection during the first cycle, and a subsequent dose escalation to 1.0 mg/m2 or further dose reduction to 0.5 mg/m2 may be considered based on patient tolerance Patients with mild hepatic impairment do not need a starting dose modification and should be treated as per the recommended dose. Efficacy and safety in children not established.

BORTEZOMIB CONTRAINDICATIONS

  • BORTEZOMIB is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of BORTEZOMIB.
  • BORTEZOMIB is contraindicated in patients with hypersensitivity (allergic reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions

BORTEZOMIB SAFETY PRECAUTIONS AND STORAGE PRECAUTIONS

In BORTEZOMIB subcutaneous administration, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, or erythematous. If local injection site reactions occur following BORTEZOMIB administration subcutaneously, a less concentrated BORTEZOMIB solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously. Intravenous administration should be considered. BORTEZOMIB treatment causes a peripheral neuropathy that is predominantly sensory; however, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ? Grade 3) during treatment with BORTEZOMIB. Caution should be used when treating patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated.Patients with risk factors for, or existing heart disease should be closely monitored.

BORTEZOMIB STORAGE

Store in a cool and dry place at room temperature Proper disposal of expired medicines BORTEZOMIB is an antineoplastic agent therefore great care has to be taken.

BEFORE USING BORTEZOMIB

You should not use BORTEZOMIB if you are allergic to bortezomib, mannitol, or boron. Make sure you are not pregnant because BORTEZOMIB can harm your unborn child. Inform you doctor of any medical conditions you have, diabetes liver problems heart problems blood pressure problems etc Inform your doctor of any other medication (prescription or non prescription) that you are taking.

MISSED DOSE

It is important to receive each scheduled BORTEZOMIB dosage as directed. If you miss a dose make sure you receive it as soon as possible but not close to your next dose if so contact your doctor to establish a way forward.

SIDE EFFECTS OF BORTEZOMIB

Most common BORTEZOMIB side effects (incidence ? 20%) include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia The following are uncommon but may occur;
  • Difficulty sleeping (Insomnia)
  • Joint pains, arthralgia, myalgias
  • Swelling of the face, hands, feet or legs (edema).
  • Low white blood cell count. (This can put you at increased risk for infection.)
  • Shortness of breath
  • Dizziness
  • Rash (see skin reactions)
  • Dehydration
  • Upper respiratory tract infection
  • Cough
  • Bone pain
  • Anxiety
  • Muscle cramps
  • Heartburn
  • Abdominal pain
  • Low blood pressure
  • Itching
  • Blurring of vision
  • Blood test abnormalities
Hair loss – BORTEZOMIB can cause hair loss in some patients.

MONITORING

  • Patients with diabetes may require close monitoring while on BORTEZOMIB therapy and adjustment of their antidiabetic medication.
  • Regular monitoring of certain blood profiles will be done by your doctor to check for reactions and adverse effects. Blood profiles including; Complete blood count (CBC), chemistry profile; Glucose, BUN (Blood Urea Nitrogen), Creatinine protein and calcium
  • Patients should be monitored for symptoms of neuropathy such as such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness

What are the most common side effects of BORTEZOMIB?

Most common BORTEZOMIB side effects (incidence ≥ 20%) include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia

Does BORTEZOMIB interact with other drugs?

It does interact with several other medications so make sure to tell your doctor of any other medication you are taking.

What happens when I miss a dose of BORTEZOMIB?

It is important that you receive each scheduled BORTEZOMIB dosage as directed. If you miss a dose make sure you receive it as soon as possible but not close to your next dose if so contact your doctor to establish a way forward.

When will my order ship?

Orders are shipped Monday through Friday, excluding legal holidays.

How do I track my order to know where it is in transit?

Every time you place an order, you'll receive an email from us notifying you of its status.

I received BORTEZOMIB for multi-myeloma for four and a half months. I was scheduled for another 4 months but reached a level of remission that did not require any more chemo. Pleased with the results.”

“Velcade is working well for, the side effects can be intense sometimes but that’s a small price to pay.”

“The pain from neuropathy in the feet, ankles and legs is excruciating. It is so bad that I cannot be on my feet for more that 2 min at a time. The worst part is, the pain just doesn’t go away.”

“The injection is relatively painless and I have had little if any side effects aside from thirst and hunger.”

“I have loss muscle mass since I started BORTEZOMIB, and I have tingling in my feet. I also don’t have very much energy. Walking can also be difficult.”

“Apart from the severe side effects of Velcade Iam content with how it is working for me.”

“You have to be satisfied with being in remission, but the neuropathy in my feet really makes me question whether or not I should have gone the transplant route.”

Store Information

payment

 

 

2015 © lifesaving.clinic

Generic Viagra   |   Viagra Online